Chimeric antigen receptor nature-killing cell therapy showed efficacy, persistence, and safety in treating systemic lupus erythematosus (SLE) in a small study presented at ACR Convergence 2024. The study involved 22 patients with active severe and refractory SLE who received an allogenic CD19-targeting CAR-NK cell treatment. Results showed high response rates in terms of disease activity and serology, with no serious adverse events reported. Patients also experienced a decrease in glucocorticoid use. The therapy demonstrated efficacy, persistence, and super safety in treating SLE, with promising outcomes observed up to 12 months follow-up.
Source link
CAR-NK cell approach achieves ‘efficacy, persistence and super safety’ in lupus
